作为单一药物,modakafusp alfa在患有复发性/耐药性多发性髓瘤的患者中进行了一项2期随机研究
Sarah A Holstein1, Shebli Atrash2, Hira Mian3
1University of Nebraska Medical Center, Omaha, Nebraska, United States.
Blood
|April 25, 2025
概括
莫达卡富斯普阿尔法在复发性/耐药性多发性骨髓瘤 (RRMM) 患者中表现出有效性,较高剂量显示出更好的反应率. 尽管早期终止,该研究证实了其作为RRMM的单剂治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
背景情况:
- 莫达卡福斯普阿尔法是一种新型免疫细胞因子,向CD38阳性细胞.
- 之前的研究已经确定了复发性/耐药性多发性骨髓瘤 (RRMM) 的可能的2期剂量.
研究的目的:
- 在患有三级耐火性RRMM的患者中优化modakafusp alfa的剂量.
- 为了评估两个固定的剂量modakafusp alfa的疗效和安全性.
主要方法:
- 在147名RRMM患者中进行了一项2期随机化剂量优化研究 (NCT03215030).
- 患者每4周接受120毫克或240毫克的modakafusp alfa.
- 由于战略原因,研究提前结束.
主要成果:
- 总体反应率 (ORR) 为32% (120毫克) 和41% (240毫克).
- 平均无进展生存时间为4.1个月 (120毫克) 和5.3个月 (240毫克).
- 在没有先前接受BCMA治疗的患者中观察到更高的ORR (46%对29%).
结论:
- 单一药物modakafusp alfa在RRMM患者中显示出已确认的疗效.
- 更高剂量 (240毫克) 显示出更好的疗效结果.
- 常见的毒性包括血小板缺血和中性质缺血.
更多相关视频
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...


